BlackRock Inc. boosted its stake in CryoPort Inc (NASDAQ:CYRX) by 7.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,048,518 shares of the consumer goods maker’s stock after buying an additional 135,471 shares during the period. BlackRock Inc. owned 5.76% of CryoPort worth $37,529,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in CYRX. Cortina Asset Management LLC bought a new position in CryoPort in the 2nd quarter valued at about $5,723,000. Handelsbanken Fonder AB acquired a new stake in CryoPort in the 2nd quarter valued at about $2,933,000. Axiom International Investors LLC DE acquired a new stake in CryoPort in the 2nd quarter valued at about $1,810,000. Monashee Investment Management LLC acquired a new stake in CryoPort in the 2nd quarter valued at about $1,374,000. Finally, Parametric Portfolio Associates LLC acquired a new stake in CryoPort in the 2nd quarter valued at about $982,000. Hedge funds and other institutional investors own 59.59% of the company’s stock.
Shares of NASDAQ CYRX opened at $14.49 on Friday. CryoPort Inc has a twelve month low of $8.28 and a twelve month high of $25.02. The company has a current ratio of 17.73, a quick ratio of 17.68 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $515.74 million, a price-to-earnings ratio of -46.74 and a beta of 0.81. The firm has a 50-day moving average of $18.33 and a two-hundred day moving average of $17.67.
A number of equities research analysts have weighed in on the stock. Svb Leerink reissued an “outperform” rating on shares of CryoPort in a report on Monday, July 15th. BidaskClub downgraded shares of CryoPort from a “sell” rating to a “strong sell” rating in a report on Saturday, October 5th. Leerink Swann assumed coverage on shares of CryoPort in a report on Monday, July 15th. They issued a “buy” rating and a $24.00 price target for the company. ValuEngine downgraded shares of CryoPort from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, B. Riley set a $26.00 price target on shares of CryoPort and gave the company a “buy” rating in a report on Friday, July 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $24.00.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
See Also: Capital Gains
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.